Passive Monitoring at Home: A Pilot Study in Parkinson Disease.
Gait speed
Parkinson disease
Quality of life
Sleep disorders
Journal
Digital biomarkers
ISSN: 2504-110X
Titre abrégé: Digit Biomark
Pays: Switzerland
ID NLM: 101707633
Informations de publication
Date de publication:
Historique:
received:
08
10
2018
accepted:
11
02
2019
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
26
2
2020
Statut:
epublish
Résumé
We conducted a pilot study using a passive radio-wave-based home monitor in individuals with Parkinson disease (PD) with a focus on gait, home activity, and time in bed. We enrolled 7 ambulatory individuals to have the device installed in the bedroom of their homes over 8 weeks and performed standard PD assessments at baseline. We evaluated the ability of the device to objectively measure gait and time in bed and to generate novel visualizations of home activity. We captured 353 days of monitoring. Mean gait speed (0.39-0.78 m/s), time in bed per day (4.4-12.1 h), and number (1.4-5.9) and duration (15.0-49.8 min) of nightly awakenings varied substantially across and within individuals. Derived gait speed correlated well with the Movement Disorder Society-Unified Parkinson's Disease Rating Scale total (
Identifiants
pubmed: 32095766
doi: 10.1159/000498922
pii: dib-0003-0022
pmc: PMC7015389
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22-30Subventions
Organisme : NINDS NIH HHS
ID : P20 NS092529
Pays : United States
Organisme : NINDS NIH HHS
ID : P50 NS108676
Pays : United States
Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Z.K., C.S., A.G., C.-Y.H., and R.H. report no disclosures related to this paper. C.G.T. has received honoraria for speaking at American Academy of Neurology courses; research support from the Michael J. Fox Foundation, American Academy of Neurology Institute, and the National Institute of Neurological Disorders and Stroke, National Institute of Health. B.F. has received research support from the Michael J. Fox Foundation. E.R.D. has received honoraria for speaking at American Academy of Neurology courses; received compensation for consulting activities from 23 and Me, Clintrex, GlaxoSmithKline, Grand Rounds, Lundbeck, MC10, MedAvante, Medico Legal services, the National Institute of Neurological Disorders and Stroke, Shire, Teva, and UCB; research support from AMC Health, Burroughs Wellcome Fund, Davis Phinney Foundation, Duke University, GlaxoSmithKline, Great Lakes Neurotechnologies, Greater Rochester Health Foundation, Huntington Study Group, the Michael J. Fox Foundation, National Science Foundation, Patient-Centered Outcomes Research Institute, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Safra Foundation, and the University of California Irvine; and stock options from Grand Rounds. D.K. has received research support from the Michael J. Fox Foundation, Novartis, and LEO Pharma.
Références
Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6495-8
pubmed: 22255826
Clin Neuropharmacol. 2000 Mar-Apr;23(2):75-81
pubmed: 10803796
JAMA Neurol. 2018 May 1;75(5):582-590
pubmed: 29379963
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Sleep. 2017 Aug 1;40(8):
pubmed: 28645156
Neurology. 2015 Mar 17;84(11):1104-13
pubmed: 25681454
Sci Rep. 2017 Feb 08;7:42084
pubmed: 28176828
IEEE Trans Biomed Eng. 2013 Oct;60(10):2925-32
pubmed: 23744661
PLoS One. 2015 Sep 17;10(9):e0138095
pubmed: 26379170
Neurology. 2009 Nov 24;73(21):1738-45
pubmed: 19933974
J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):629-35
pubmed: 12438461
J Neurol Phys Ther. 2014 Oct;38(4):233-8
pubmed: 25198866
J Geriatr Phys Ther. 2016 Oct-Dec;39(4):165-70
pubmed: 26428902